Pradaxa Information

What is Pradaxa?

Pradaxa® is the name under which Boehringer Ingelheim Pharmaceuticals, Inc. markets a prescription anticoagulant medication generically called dabigatran.  

Pradaxa is a blood-thinning drug used to reduce the risk of stroke and blood clots in people with atrial fibrillation not caused by a heart valve problem.  Since coming on the market in October 2010 the FDA has received numerous Adverse Event Reports involving serious bleeding side effects such as hemorrhages. Symptoms of these medical complications include:

• Coughing up blood
• Severe bleeding
• Vomiting blood

Further, medical studies have associated Pradaxa with an increased risk of heart attack, or myocardial infarction (MI), and acute coronary syndrome (ACS).

All content by attorney Tom Lamb

Pradaxa Legal Information

Pradaxa Class Actions vs. Individual Lawsuits

We believe that people who suffered a serious injury or death due to their use of Pradaxa capsules are better served when an individual lawsuit is filed on their behalf. A serious injury or death case should not be filed as part of any Pradaxa class actions together with the claims of many other people who may have had different injuries caused by these birth control pills.

Legal Compensation for Pradaxa Side Effects

If you experienced serious side effects from the use of Pradaxa, or a person died due to an adverse reaction while taking Pradaxa, you may have a claim for legal compensation. Such claims involving a serious injury or death caused by the use of Pradaxa are made by filing a lawsuit in court. All states have statutes of limitations that determine the deadlines by which to file lawsuits involving Pradaxa side effects.

Free Pradaxa Case Evaluation

Free Pradaxa Case Evaluation by Drug Injury Lawyer Tom Lamb

The information you provide to us for this Free Case Evaluation will be treated as strictly confidential.  You will get a reply from us no later than the next business day.  Submitting a case evaluation does not obligate you to hire our law firm for your lawsuit.  We handle all cases on a contingency fee basis, which means that you will make no payment for our legal services until after we have succeeded in getting legal compensation for you.

Pradaxa Medical Information

Pradaxa label change: This January 17, 2012 FDA approval letter shows the revisions being made to current Pradaxa Prescribing Information -- also referred to as the package insert or the label. 

The "FDA Drug Safety Communication: Safety review of post-market reports of serious bleeding events with the anticoagulant Pradaxa (dabigatran etexilate mesylate)" issued December 7, 2011 by the FDA about their current evaluation concerning the safety of Pradaxa.

The so-called "Dear Doctor" letter sent to healthcare professionals in the United Kingdom (UK) on October 27, 2011 to inform them of new recommendations to assess renal function:

Direct Healthcare Professional Communication on the importance of assessing renal function in patients treated with ▼Pradaxa® (dabigatran etexilate).

Drug Injury Watch: Pradaxa News and Commentary